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Value of the data {#sec0001a}
=================

•Indazole tethered oxadiazole (OTD) derivatives have significant anti-cancer activity against hepatocellular carcinoma (HCC) cells.•The given procedure for the synthesis of Indazole tethered oxadiazoles could be useful for organic chemists to develop novel drugs.•The given spectroscopic data on the Indazole tethered oxadiazoles could be useful for organic chemists for synthesis of OTDs.

1. Data description {#sec0001}
===================

A series of Indazole tethered oxadiazoles (OTDs) (**3a-k**) were synthesized by refluxing N-methyindazole-acid hydrazide with different aromatic carboxylic acids (**2a-k**) in phosphorous oxychloride [@bib0001]. The synthetic route and structure of final compounds were given in [Fig. 1](#fig0001){ref-type="fig"}. All the final compounds (**3a-k**) were characterized by ^1^H NMR, ^13^C NMR, LCMS and HPLC for active compounds **3**c, **3d, 3f, 3i**. All the spectra data are provided in this article ([Fig. 2](#fig0002){ref-type="fig"}, [Fig. 3](#fig0003){ref-type="fig"}, [Fig. 4](#fig0004){ref-type="fig"}, [Fig. 5](#fig0005){ref-type="fig"}, [Fig. 6](#fig0006){ref-type="fig"}, [Fig. 7](#fig0007){ref-type="fig"}, [Fig. 8](#fig0008){ref-type="fig"}, [Fig. 9](#fig0009){ref-type="fig"}, [Fig. 10](#fig0010){ref-type="fig"}, [Fig. 11](#fig0011){ref-type="fig"}, [Fig. 12](#fig0012){ref-type="fig"}, [Fig. 13](#fig0013){ref-type="fig"}, [Fig. 14](#fig0014){ref-type="fig"}, [Fig. 15](#fig0015){ref-type="fig"}, [Fig. 16](#fig0016){ref-type="fig"}, [Fig. 17](#fig0017){ref-type="fig"}, [Fig. 18](#fig0018){ref-type="fig"}, [Fig. 19](#fig0019){ref-type="fig"}, [Fig. 20](#fig0020){ref-type="fig"}, [Fig. 21](#fig0021){ref-type="fig"}, [Fig. 22](#fig0022){ref-type="fig"}, [Fig. 23](#fig0023){ref-type="fig"}, [Fig. 24](#fig0024){ref-type="fig"}, [Fig. 25](#fig0025){ref-type="fig"}, [Fig. 26](#fig0026){ref-type="fig"}, [Fig. 27](#fig0027){ref-type="fig"}, [Fig. 28](#fig0028){ref-type="fig"}, [Fig. 29](#fig0029){ref-type="fig"}, [Fig. 30](#fig0030){ref-type="fig"}, [Fig. 31](#fig0031){ref-type="fig"}, [Fig. 32](#fig0032){ref-type="fig"}, [Fig. 33](#fig0033){ref-type="fig"}, [Fig. 34](#fig0034){ref-type="fig"}, [Fig. 35](#fig0035){ref-type="fig"}, [Fig. 36](#fig0036){ref-type="fig"}, [Fig. 37](#fig0037){ref-type="fig"}, [Fig. 38](#fig0038){ref-type="fig"}). The anti-cancer activities of the newly synthesized OTDs are given in [Fig. 39](#fig0039){ref-type="fig"}. The Crystalographic data for compounds **3a, 3** **h** & **3k** have been deposited with the Cambridge Crystalographic Data centre., CCDC No. 1992373, 1992374 and 1992375. Copies of the data can be obtained free of charge upon request to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: 044 (0) 1223 336033 or e-mail: deposit\@ccdc.cam.ac.uk).Fig. 1Synthetic scheme and structure of Oxadiazoles **3a-3k.**Fig 1Fig. 2^1^H NMR spectrum of **3a**.Fig 2Fig. 3^13^C NMR spectrum of **3a**.Fig 3Fig. 4Mass spectrum of **3a**.Fig 4Fig. 5^1^H NMR spectrum of **3b**.Fig 5Fig. 6^13^C NMR spectrum of **3b**.Fig 6Fig. 7Mass spectrum of **3b**.Fig 7Fig. 8^1^H NMR spectrum of **3c**.Fig 8Fig. 9^13^C NMR spectrum of **3c**.Fig 9Fig. 10Mass spectrum of **3c**.Fig 10Fig. 11HPLC spectrum of **3c**.Fig 11Fig. 12^1^H NMR spectrum of **3d**.Fig 12Fig. 13^13^C NMR spectrum of **3d**Fig 13Fig. 14Mass spectrum of **3d**Fig 14Fig. 15HPLC spectrum of **3d**Fig 15Fig. 16^1^HNMR spectrum of **3e**.Fig 16Fig. 17^13^C NMR spectrum of **3e**.Fig 17Fig. 18Mass spectrum of **3e**.Fig 18Fig. 19^1^H NMR spectrum of **3f**.Fig 19Fig. 20^13^C NMR spectrum of **3f**.Fig 20Fig. 21Mass spectrum of **3f**.Fig 21Fig. 22HPLC spectrum of **3f**.Fig 22Fig. 23^1^HNMR spectrum of **3g**.Fig 23Fig. 24^13^C NMR spectrum of **3g**.Fig 24Fig. 25Mass spectrum of **3g**.Fig 25Fig. 26^1^HNMR spectrum of **3h**.Fig 26Fig. 27^13^C NMR spectrum of **3h**.Fig 27Fig. 28Mass spectrum of **3h**.Fig 28Fig. 29^1^HNMR spectrum of **3i**.Fig 29Fig. 30^13^C NMR spectrum of **3i**.Fig 30Fig. 31Mass spectrum of **3i**.Fig 31Fig. 32HPLC spectrum of **3i**.Fig 32Fig. 33^1^H NMR spectrum **3j**.Fig 33Fig. 34^13^C NMR Spectrum of **3j**.Fig 34Fig. 35Mass spectrum of **3j**.Fig 35Fig. 36^1^H NMR spectrum of **3k**.Fig 36Fig. 37^13^CNMR spectrum of **3k**.Fig 37Fig. 38Mass spectrum of **3k**.Fig 38Fig. 39Anti-proliferative activity of Oxadiazoles as determined by MTT Assay.Fig 39

2. Experimental design, materials and methods {#sec0002}
=============================================

2.1. General information {#sec0003}
------------------------

The reagents used for the reaction are commercially available reagent class and were used without further purification. The chemicals were purchased from Sigma-Aldrich, TCI or SD-Fine. The reactions were monitored by thin layer chromatography using pre-coated Merck silica gel 60 F254 plates and analytical TLCs were conducted using ethyl acetate and hexanes as eluent. Then the spots were observed under UV light. The final compounds were purified by silica gel column chomatography using ethyl acetate and hexane as eluent and organic solvents were concentrated under reduced pressure on the rotary evaporator.

The purified samples were dissolved in either CDCl~3~ or DMSO-d^6^ to acquire the NMR spectra using Agilent NMR. ^1^H NMR and ^13^C NMR were recorded at 400 and 100 MHz respectively. The ^1^H NMR Data are expressed in chemical shift (δ, ppm) and multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = doublet of triplet, dd = doublet of doublets, m = multiplet), coupling constant (*J,* Hz) and integration. The LCMS measurments were performed on Agilent LC-MS using 2 mg/mL of the solutions in HPLC grade acetonitrile or methanol. The HPLC was recorded using Waters (USA) connected to W2998 Photo-Diode Array Detector, Column: Syncronis-C18, 4.6 × 150 mm, 5 μm, Mobile Phase-A: 0.1% Formic acid in Water, Mobile Phase-B: Acetonitrile.

The OTDs were screened for their anti-proliferative potency against human hepatocellular carcinoma cell lines (HepG2, HCCLM3) and normal Liver human cell line (LO2) using MTT assay [@bib0002].

2.2. General procedure {#sec0004}
----------------------

To a stirred solution of 1-methyl-1H-indazole-3-carboxylic acid (1 gm, 0.0056 mol) in anhydrous ethanol (15 mL). The catalytic amount of conc. Sulfuric acid was added and refluxed for 6 h. The excess of ethanol was concentrated off on a rota-evaporator. The reaction mixture was cooled and the contents of the flask were transferred to a separating funnel containing about 250 mL of distilled water. The synthesized ester was extracted three times with 50 mL Ethyl acetate each. The organic layers were mixed and washed with brine and dried over Sodium sulfate. Ethyl acetate was then distilled off under reduced pressure to get the ester **1** in 89% yield.

To a stirred solution of ethyl 1-methyl-1H-indazole-3-carboxylate **1** (0.5 gm, 0.0024 mol) taken in a round bottom flask containing 250 mL of ethanol, 99% hydrazine hydrate (0.15 mL, 0.0029 mol) was added and refluxed for 6 h. The excess of ethanol and hydrazine hydrate were distilled off under reduced pressure. Ice-cold water was poured into the above reaction mixture and the precipitate so obtained was filtered off and recrystallized from a suitable solvent and the product N-methy indazole-acid hydrazide [@bib0003] was obtained in 92% yield.

2.3. Procedure for the synthesis of 3a-k {#sec0005}
----------------------------------------

A mixture of 1-methyl-1H-indazole-3-carbohydrazide (1eq), different aromatic acids (**2a-k)** (1eq) and phosphorus oxychloride (POCl~3~) (2 mL) were taken in round bottom flask and refluxed for 8 h. The contents of the reaction mixture were cooled and poured onto the crushed ice. The solid obtained was filtered, treated with potassium carbonate, washed with water and purified by column chromatography using ethyl acetate and hexane as eluent to afford oxadiazoles.

2. 3 characterization data {#sec0006}
--------------------------

**2-(1-methyl-1H-indazol-3-yl)-5-phenyl-1,3,4-oxadiazole, 3a:**

White Solid; mp178--182˚C; 81% yield;^1^H NMR (CDCl~3~, 400 MHz) δ: 8.35(d, *J*=8.4 Hz, 1H), 8.18--8.16 (m, 2H), 7.44--7.49 (m,5 H), 7.31--7.33 (m, 1H), 4.16 (s, 3H); ^13^C NMR: 163.05, 159.19, 139.97, 130.74, 128.49, 128.01, 126.49, 126.19, 122.74, 122.01, 121.35, 121.04, 108.45, 35.33; LCMS (ESI): *m/z* Calcd for C~16~H~12~N~4~O \[M + H\] ^+^: 277.1044; Found: 277.0432.

**2-(2-chlorophenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole, 3b:**White solid; mp 160--164˚C; 78% yield;^1^H NMR (CDCl~3~, 400 MHz) δ: 8.08--8.6(m,1H),8.05--7.45 (m,1H), 7.45--7.43 (m,1H),7.42--7.37(m,3H), 7.36--7.31(m,2H) 4.15 (s,3H);^13^CNMR:161.32,159.56, 139.97,132.34,131.36,130.38,130.21,128.22,126.45,126.03,122.08,122.37,120.90,108.49,35.36; LCMS (ESI): *m/z* Calcd for C~16~H~11~ClN~4~O \[M + H\] ^+^: 311.0654; Found:310.9835.

**2-(4-methoxyphenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole,3c:**Off white solid; mp 196--200˚C; 83% yield;^1^H NMR (CDCl~3~, 400 MHz) δ: 8.39 (d, *J*=8 Hz,1H), 8.15 (d, J=8. 8 Hz,2H), 7.49--7.45(m,2H),7.37--7.34(m,1H),7.01(d, *J*=8.8 Hz, 2H),4.20(s,3H),3.87 (s, 3H); ^13^CNMR:164.00,162.35,159.73,140.94, 128.97, 128.544, 127.44,122.91, 122.28,122.08, 116.24, 114.43,109.42,55.46,36.29;LCMS (ESI): *m/z* Calcd for C~17~H~14~N~4~O~2~\[M + H\] ^+^: 307.1150; Found:307.0354.

**2-(3-chlorophenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole,3d:** White solid; mp180--184˚C; 86% yield;^1^H NMR (CDCl~3~,400 MHz)δ: 8.41(d, *J*=8.4 Hz,1H), 8.23--8.22(m,1H),8.12 (d *J*=8 Hz, 1H),7.54--7.46(m,4H), 7.417.37 (m,1H), 4.22(s,3H); ^13^CNMR: 162.90, 160.47, 141.01, 135.21,131.75,130.36,129.31,127.55,127.09,125.42,125.26,123.13,122.40,122.02,109.47,36.33;LCMS (ESI): *m/z* Calcd for C~16~H~11~ClN~4~O\[M + H\] ^+^: 311.0654; Found:310.9835.

**4-(5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazol-2-yl)phenol,3e:**off white solid; mp170--174˚C; 88% yield;^1^H NMR (DMSO-D6, 400 MHz) δ: 10.24 (s,1H),8.22 (s, 1H), 8.12(d, *J*=7.2 Hz,1H),7.9(d, *J*=8 Hz,1H),7.56 (d, *J*=7.6 Hz,1H),7.29--7.26 (m, 2H), 6.95(d, *J*=8.4 Hz,2H), 3.87 (s,3H);^13^C NMR:162.51, 160.89, 137.45, 132.16, 128.70, 124.89, 123.27, 121.86, 120.86, 116.61,114.97, 111.27, 99.03, 33.50;LCMS (ESI): *m/z* Calcd for C~16~H~12~N~4~O~2~\[M + H\] ^+^: 293.0993; Found:293.0221.

**2-(2-bromophenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole,3f:**white solid; mp160--165˚C; 88% yield;^1^HNMR(CDCl~3~,400 MHz) δ:8.41(d, *J*=8.4 Hz,1H), 8.06--8.04(m,1H),7.68--64(m,1H),7.51--7.45(m,3H),7.41--7.35(m,2H),4.21(s,3H);^13^C NMR:162.85,160.61,140.9, 134.49,132.41,131.80,129.26,127.52,127.43,125.28,123.07,122.38,121.93(2),109.47,36.32;LCMS (ESI): *m/z* Calcd for C~16~H~11~BrN~4~O\[M + H\] ^+^: 356.0095; Found:356.9287.

**2-(1-methyl-1H-indazol-3-yl)-5-(m-tolyl)-1,3,4-oxadiazole,3 g:**off white solid; mp150--152˚C; 85% yield;^1^H NMR (CDCl~3~, 400 MHz) δ: 8.41(d, *J*=8.4 Hz,1H), 8.04--8.01(m,2H), 7.50--7.34(m,5H), 4.21 (s,3H), 2.44 (s,3H); ^13^C NMR: 164.21, 160.10, 140.98, 138.89, 132.89, 132.54, 129.57, 128.90, 127.66, 127.47, 124.36, 123.61, 122.61, 122.97, 122.35, 122.08, 109.42, 36.30,29.67;LCMS (ESI): *m/z* Calcd for C~17~H~14~N~4~O\[M + H\] ^+^: 291.1201; Found: 291.0395.

**2-(1-methyl-1H-indazol-3-yl)-5-(p-tolyl)-1,3,4-oxadiazole,3h:**off white solid; mp182--186˚C; 83% yield; ^1^H NMR (CDCl~3~, 400 MHz) δ: 8.4(d, *J*=8 Hz,1H), 8.11--8.09 (m,2H), 7.5--7.47(m,2H), 7.38--7.31(m,3H), 4.20(s,3H), 2.43(s,3H); ^13^C NMR: 164.20, 159.94, 142.30, 140.95,129.71,129.58,127.45,127.14,122.95,122.31,122.07,120.95,109.43,36.30,21.67;LCMS (ESI): *m/z* Calcd for C~17~H~14~N~4~O\[M + H\] ^+^: 291.120; Found: 291.0395.

**2-(3-bromophenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole,3i**: Pale yellow solid; mp172--176˚C; 77% yield; ^1^H NMR (CDCl~3~, 400 MHz) δ: 8.42--8.37(m,2H),8.17 (d, *J*=8 Hz, 1H), 7.68 (d, *J*=8 Hz, 1H),7.52--7.50 (m,2H), 7.437.37 (m,2H), 4.23 (s,3H); ^13^C NMR: 162.75,160.48,140.99,134.70,130.59,129.92,129.26,127.58,125.72,125.57,123.15,123.08,122.37,122.02,109.51,36.38;LCMS (ESI): *m/z* Calcd for C~16~H~11~BrN~4~O\[M + H\] ^+^: 355.0116; Found: 354.9381.

**2-(4-chlorophenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole,3j:**off white solid; mp180--186˚C; 87% yield;^1^H NMR (CDCl~3~, 400 MHz) δ: 8.38 (d, *J*= 8 Hz,1 H), 8 . 1 4 (d, *J*=8.4 Hz, 2H), 7.50--7.46 (m.4H), 7.38--7.34 (m,1H), 4.02(s,3H); ^13^C NMR: 163.21,160.30, 140.98, 137.98, 129.38, 128.41, 127.50, 123.06, 122.35, 122.25, 121.99,109.46,36.30;LCMS (ESI): *m/z* Calcd for C~16~H~11~ClN~4~O\[M + H\] ^+^: 311.0621; Found: 310.9912.

**2-(4-bromophenyl)-5-(1-methyl-1H-indazol-3-yl)-1,3,4-oxadiazole,3k:**off white solid; mp184--190˚C; 85% yield;^1^H NMR (CDCl~3~, 400 MHz) δ: 8.39(d, *J*=8.4 Hz, 1H), 8.09--8.06 (m,2H), 7.68--7.65 (m,2H), 7.501--7.49 (m,2H),7.39--7.35(m,1H),4.21(s,3H);^13^C NMR:163.31, 160.32, 140.97, 132.36, 129.28, 128.56, 127.54, 126.44, 123.11, 122.65, 122.36, 121.99,109.49,36.36;LCMS (ESI): *m/z* Calcd for C~16~H~11~BrN~4~O\[M + H\] ^+^: 356.0095; Found: 356.9370.

Declaration of Competing Interest
=================================

The authors declare that they are no known competing financial interests reported in this article.

This research was supported by the Council of Scientific and Industrial Research (No. 02(0291)17/EMR-II), Department of Biotechnology (BT/PR24978/NER/95/938/2017) and Vision Group on Science and Technology, Government of Karnataka, India to Basappa.
